• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

European Hematology Association (EHA) 2024 Hybrid Congress

June 13 - 16, 2024

  1. Acalabrutinib
  2. AZD0486
  3. Sabestomig (AZD7789)
  4. AZD9829
  5. AZD5492
  6. Oncology Unbranded

pdf

Acalabrutinib plus Bendamustine and Rituximab in untreated mantle cell lymphoma: Results from the phase 3, double-blind, placebo-controlled ECHO trial

PDF

Outcomes of EPIC: A non-interventional, observational study of patients with chronic lymphocytic leukaemia treated with first-line acalabrutinib via the UK early access programme; interim analyses, follow-up of ELEVATE-TN

pdf

Impact of acalabrutinib treatment by line of therapy in patients with chronic lymphocytic leukemia: Pooled analysis from ELEVATE-TN, ELEVATE-RR, and ASCEND

pdf

Impact of first-year dose modifications in patients with chronic lymphocytic leukemia treated with acalabrutinib

pdf

Interim results from ASSURE: A Phase 3b safety study of acalabrutinib in patients with chronic lymphocytic leukemia

pdf

Real-world use and effectiveness of acalabrutinib in chronic lymphocytic leukaemia: The National Acalabrutinib Observational Study (NAOS)

pdf

AZD0486, a novel CD19xCD3 T-cell engager, shows durable responses in patients with relapsed/refractory follicular lymphoma: update on efficacy and safety

pdf

Safety and efficacy results from an open-label, Phase 1/2 trial of sabestomig (AZD7789) in patients with relapsed/refractory classical Hodgkin lymphoma previously treated with anti-PD-(L)1 therapies

pdf

AZD9829 demonstrates combination benefit with HMA and venetoclax in AML cell lines and primary patient samples

pdf

Pre-clinical development of a CD8-guided T cell engager for B-non-Hodgkin lymphoma indications

pdf

Diversifying clinical trial enrollment: Developing a novel method of clinical trial site selection to improve clinical trial diversity

HTML

Real-world disease characteristics and first line therapy in patients with chronic lymphocytic leukemia in Bulgaria: The describe study (interim analysis)

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Request a field medical follow-up

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice